Araştırma Makalesi
BibTex RIS Kaynak Göster

Effects of T-PRF and A-PRF on the Osteogenic Biomarkers in Intrabony Defects of Periodontitis Patients

Yıl 2023, , 248 - 254, 29.09.2023
https://doi.org/10.7126/cumudj.1253515

Öz

Background: Different derivatives of platelet-rich fibrin (PRF) have been developed but the efficacy of these derivatives in tissue healing and regeneration is still unclear. The aim of this study was to evaluate the effects of titanium-prepared PRF (T-PRF) and advanced PRF (A-PRF) on osteogenic biomarkers in gingival crevicular fluid (GCF) and clinical parameters.
Methods: Seventeen systemically healthy participants with 30 bilateral infrabony defects were recruited. Following phase I periodontal therapy, intrabony defects were treated either with A-PRF+open flap debridement (OFD) or T-PRF+OFD. Plaque index (PI), gingival index (GI), pocket depth (PD), clinical attachment loss (CAL) was recorded at the baseline and 6th month after treatment. GCF samples were collected at the baseline and 3rd, 6th months after surgery. Nuclear factor receptor activator (RANK), receptor activator nuclear kappa-B ligand (RANKL), osteoprotegerin (OPG) and tumor necrosis factor alpha converting enzyme (TACE) in GCF samples were analyzed by human enzyme-linked immunosorbent assay (ELISA).
Results: In both groups, statistically significant changes were observed in clinical parameters, however, there was no difference between the groups. In terms of osteogenic biomarkers in GCF, there were no statistically significant differences between and within the groups.
Conclusion: Different derivatives of PRF can be used to enhance the clinical outcomes of intrabony defects in periodontitis.

Destekleyen Kurum

This research was supported by the Scientific Research Project Fund of Kırıkkale University

Proje Numarası

2015/074

Kaynakça

  • 1. Froum S, Gomez C, Breault MR. Current concepts of periodontal regeneration. N Y State Dent J 2002;68:14–22.
  • 2. Heitz-Mayfield LJ, Trombelli L, Heitz F, Needleman I, Moles D. A systematic review of the effect of surgical debridement vs non-surgical debridement for the treatment of chronic periodontitis. J Clin Periodontol 2002;29:92–102.
  • 3. Trombelli L, Heitz-Mayfield LJ, Needleman I, Moles D, Scabbia A. A systematic review of graft materials and biological agents for periodontal intraosseous defects. J Clin Periodontol 2002;29:117–135.
  • 4. Matras H. Effect of various fibrin preparations on reimplantations in the rat skin. Osterr Z Stomatol 1970;67:338-359.
  • 5. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638-646.
  • 6. Choukroun J, Adda F, Schoeffer C, Vervelle A. PRF: An opportunity in perio implantology. Implantodontie 2000;42:55-62.
  • 7. Dohan DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun’s platelet-rich fibrin (PRF): A gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 2009;27:63-69.
  • 8. Okuda K, Kawase T, Momose M, Murata M, Saito Y, Suzuki H, Wolff LF, Yoshie H. Platelet-rich plasma contains high levels of platelet derived growth factor and transforming growth factor-B and modulates the proliferation of periodontally related cells in vitro. J Periodontol 2003;74:849–857.
  • 9. Anzai J, Kitamura M, Nozaki T, Nagayasu T, Terashima A, Asano T, Murakami S. Effects of concomitant use of fibroblast growth factor (FGF)-2 with beta-tricalcium phosphate (beta-TCP) on the beagle dog 1-wall periodontal defect model. Biochem Biophysic Res Com 2010;403:345–350.
  • 10. Agrawal AA. Evolution, current status and advances in application of platelet concentrate in periodontics and implantology. World J Clin Cases 2017;5(5):159-171.
  • 11. Cieslik-Bielecka A, Choukroun J, Odin G, Dohan Ehrenfest DM. L-PRP/L-PRF in esthetic plastic surgery, regenerative medicine of the skin and chronic wounds. Curr Pharm Biotechnol 2012;13:1266-1277.
  • 12. Del Corso M, Vervelle A, Simonpieri A, Jimbo R, Inchingolo F, Sammartino G, Dohan Ehrenfest DM. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) fibrin (PRF) in oral and maxillofacial surgery part 1: Periodontal and dentoalveolar surgery. Curr Pharm Biotechnol 2012;13:1207-1230.
  • 13. Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J 2014;4:3-9.
  • 14. Eren G, Atilla G. Platelet-rich fibrin in the treatment of bilateral gingival recessions. Cli Adv Periodontics 2012;2:154-160.
  • 15. Thorat M, Pradeep AR, Pallavi B. Clinical effect of autologous platelet-rich fibrin in the treatment of intra-bony defects: a controlled clinical trial. J Clin Periodontol 2011;38:925-932.
  • 16. Sharma A, Pradeep AR. Autologous platelet-rich fibrin in the treatment of mandibular degree II furcation defects: a randomized clinical trial. J Periodontol 2011;82:1396-1403.
  • 17. Chang YC, Zhao JH. Effects of platelet-rich fibrin on human periodontal ligament fibroblasts and application for periodontal infrabony defects. Aust Dent J 2011;56:365–371.
  • 18. Choukroun J. Advanced PRF and i-PRF: Platelet concentrate or blood concentrate? J Periodontal Med Clin Pract 2014;1:3.
  • 19. Tunalı M, Özdemir H, Küçükodacı Z, Akman S, Fıratlı E. In vivo evaluation of titanium-prepared platelet-rich fibrin (T-PRF): a new platelet concentrate. Br J Oral Maxillofac Surg 2013;51:438-443.
  • 20. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-553.
  • 21. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H, Atilla G, Hughes FJ, Belibasakis GN. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 2007;34:370-376.
  • 22. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613-13618.
  • 23. Bostanci N, Emingil G, Afacan B, Han B, Ilgenli T, Atilla G, HughesFJ, Belibasakis GN. Tumor necrosis factor-alpha-converting enzyme (TACE) levels in periodontal diseases. J Dent Res 2008;87:273-277.
  • 24. Singh MP, Mehta DS. Clinical evaluation of Biogran as a graft material in the treatment of periodontal osseous defects. J Indian Soc Periodontol 2000;3:69–72.
  • 25. Shah M, Deshpande N, Bharwani A, Nadig P, Doshi V, Dave D. Effectiveness of autologous platelet-rich fibrin in the treatment of intra-bony defects: A systematic review and meta-analysis. J Indian Soc Periodontol 2014;18(6):698-704.
  • 26. Chatterjee A, Pradeep AR, Garg V, Yajamanya S, Ali MM, Priya VS. Treatment of periodontal intrabony defects using autologous platelet-rich fibrin and titanium platelet-rich fibrin: a randomized, clinical, comparative study. J Investig Clin Dent 2017;8(3).
  • 27. Arabaci T, Albayrak M. Titanium-prepared platelet-rich fibrin provides advantages on periodontal healing: A randomized split-mouth clinical study. J Periodontol 2018;89(3):255-264.
  • 28. Dereka XE, Markopoulou CE, Fanourakis G, Tseleni-Balafouta S, Vrotsos IA. RANKL and OPG mRNA level after non-surgical periodontal treatment. Inflammation 2010;33:200–206.
  • 29. Buduneli N, Buduneli E, Kutukculer N. Interleukin-17, RANKL, and osteoprotegerin levels in gingival crevicular fluid from smoking and non-smoking patients with chronic periodontitis during initial periodontal treatment. J Periodontol 2009;80:1274–1280.
  • 30. Bostanci N, Saygan B, Emingil G, Atilla G, Belibasakis GN. Effect of periodontal treatment on receptor activator of NF-kappaB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. J Clin Periodontol 2011;38:428–433.
Yıl 2023, , 248 - 254, 29.09.2023
https://doi.org/10.7126/cumudj.1253515

Öz

Proje Numarası

2015/074

Kaynakça

  • 1. Froum S, Gomez C, Breault MR. Current concepts of periodontal regeneration. N Y State Dent J 2002;68:14–22.
  • 2. Heitz-Mayfield LJ, Trombelli L, Heitz F, Needleman I, Moles D. A systematic review of the effect of surgical debridement vs non-surgical debridement for the treatment of chronic periodontitis. J Clin Periodontol 2002;29:92–102.
  • 3. Trombelli L, Heitz-Mayfield LJ, Needleman I, Moles D, Scabbia A. A systematic review of graft materials and biological agents for periodontal intraosseous defects. J Clin Periodontol 2002;29:117–135.
  • 4. Matras H. Effect of various fibrin preparations on reimplantations in the rat skin. Osterr Z Stomatol 1970;67:338-359.
  • 5. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:638-646.
  • 6. Choukroun J, Adda F, Schoeffer C, Vervelle A. PRF: An opportunity in perio implantology. Implantodontie 2000;42:55-62.
  • 7. Dohan DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun’s platelet-rich fibrin (PRF): A gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 2009;27:63-69.
  • 8. Okuda K, Kawase T, Momose M, Murata M, Saito Y, Suzuki H, Wolff LF, Yoshie H. Platelet-rich plasma contains high levels of platelet derived growth factor and transforming growth factor-B and modulates the proliferation of periodontally related cells in vitro. J Periodontol 2003;74:849–857.
  • 9. Anzai J, Kitamura M, Nozaki T, Nagayasu T, Terashima A, Asano T, Murakami S. Effects of concomitant use of fibroblast growth factor (FGF)-2 with beta-tricalcium phosphate (beta-TCP) on the beagle dog 1-wall periodontal defect model. Biochem Biophysic Res Com 2010;403:345–350.
  • 10. Agrawal AA. Evolution, current status and advances in application of platelet concentrate in periodontics and implantology. World J Clin Cases 2017;5(5):159-171.
  • 11. Cieslik-Bielecka A, Choukroun J, Odin G, Dohan Ehrenfest DM. L-PRP/L-PRF in esthetic plastic surgery, regenerative medicine of the skin and chronic wounds. Curr Pharm Biotechnol 2012;13:1266-1277.
  • 12. Del Corso M, Vervelle A, Simonpieri A, Jimbo R, Inchingolo F, Sammartino G, Dohan Ehrenfest DM. Current knowledge and perspectives for the use of platelet-rich plasma (PRP) fibrin (PRF) in oral and maxillofacial surgery part 1: Periodontal and dentoalveolar surgery. Curr Pharm Biotechnol 2012;13:1207-1230.
  • 13. Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J 2014;4:3-9.
  • 14. Eren G, Atilla G. Platelet-rich fibrin in the treatment of bilateral gingival recessions. Cli Adv Periodontics 2012;2:154-160.
  • 15. Thorat M, Pradeep AR, Pallavi B. Clinical effect of autologous platelet-rich fibrin in the treatment of intra-bony defects: a controlled clinical trial. J Clin Periodontol 2011;38:925-932.
  • 16. Sharma A, Pradeep AR. Autologous platelet-rich fibrin in the treatment of mandibular degree II furcation defects: a randomized clinical trial. J Periodontol 2011;82:1396-1403.
  • 17. Chang YC, Zhao JH. Effects of platelet-rich fibrin on human periodontal ligament fibroblasts and application for periodontal infrabony defects. Aust Dent J 2011;56:365–371.
  • 18. Choukroun J. Advanced PRF and i-PRF: Platelet concentrate or blood concentrate? J Periodontal Med Clin Pract 2014;1:3.
  • 19. Tunalı M, Özdemir H, Küçükodacı Z, Akman S, Fıratlı E. In vivo evaluation of titanium-prepared platelet-rich fibrin (T-PRF): a new platelet concentrate. Br J Oral Maxillofac Surg 2013;51:438-443.
  • 20. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-553.
  • 21. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H, Atilla G, Hughes FJ, Belibasakis GN. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 2007;34:370-376.
  • 22. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613-13618.
  • 23. Bostanci N, Emingil G, Afacan B, Han B, Ilgenli T, Atilla G, HughesFJ, Belibasakis GN. Tumor necrosis factor-alpha-converting enzyme (TACE) levels in periodontal diseases. J Dent Res 2008;87:273-277.
  • 24. Singh MP, Mehta DS. Clinical evaluation of Biogran as a graft material in the treatment of periodontal osseous defects. J Indian Soc Periodontol 2000;3:69–72.
  • 25. Shah M, Deshpande N, Bharwani A, Nadig P, Doshi V, Dave D. Effectiveness of autologous platelet-rich fibrin in the treatment of intra-bony defects: A systematic review and meta-analysis. J Indian Soc Periodontol 2014;18(6):698-704.
  • 26. Chatterjee A, Pradeep AR, Garg V, Yajamanya S, Ali MM, Priya VS. Treatment of periodontal intrabony defects using autologous platelet-rich fibrin and titanium platelet-rich fibrin: a randomized, clinical, comparative study. J Investig Clin Dent 2017;8(3).
  • 27. Arabaci T, Albayrak M. Titanium-prepared platelet-rich fibrin provides advantages on periodontal healing: A randomized split-mouth clinical study. J Periodontol 2018;89(3):255-264.
  • 28. Dereka XE, Markopoulou CE, Fanourakis G, Tseleni-Balafouta S, Vrotsos IA. RANKL and OPG mRNA level after non-surgical periodontal treatment. Inflammation 2010;33:200–206.
  • 29. Buduneli N, Buduneli E, Kutukculer N. Interleukin-17, RANKL, and osteoprotegerin levels in gingival crevicular fluid from smoking and non-smoking patients with chronic periodontitis during initial periodontal treatment. J Periodontol 2009;80:1274–1280.
  • 30. Bostanci N, Saygan B, Emingil G, Atilla G, Belibasakis GN. Effect of periodontal treatment on receptor activator of NF-kappaB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. J Clin Periodontol 2011;38:428–433.
Toplam 30 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Original Research Articles
Yazarlar

Siddika Selva Süme Keşir 0000-0003-0817-2803

Meltem Hendek 0000-0003-1518-4159

Üçler Kısa 0000-0002-8131-6810

Ebru Olgun 0000-0001-5001-8151

Proje Numarası 2015/074
Yayımlanma Tarihi 29 Eylül 2023
Gönderilme Tarihi 21 Şubat 2023
Yayımlandığı Sayı Yıl 2023

Kaynak Göster

EndNote Süme Keşir SS, Hendek M, Kısa Ü, Olgun E (01 Eylül 2023) Effects of T-PRF and A-PRF on the Osteogenic Biomarkers in Intrabony Defects of Periodontitis Patients. Cumhuriyet Dental Journal 26 3 248–254.

Cumhuriyet Dental Journal (Cumhuriyet Dent J, CDJ) is the official publication of Cumhuriyet University Faculty of Dentistry. CDJ is an international journal dedicated to the latest advancement of dentistry. The aim of this journal is to provide a platform for scientists and academicians all over the world to promote, share, and discuss various new issues and developments in different areas of dentistry. First issue of the Journal of Cumhuriyet University Faculty of Dentistry was published in 1998. In 2010, journal's name was changed as Cumhuriyet Dental Journal. Journal’s publication language is English.


CDJ accepts articles in English. Submitting a paper to CDJ is free of charges. In addition, CDJ has not have article processing charges.

Frequency: Four times a year (March, June, September, and December)

IMPORTANT NOTICE

All users of Cumhuriyet Dental Journal should visit to their user's home page through the "https://dergipark.org.tr/tr/user" " or "https://dergipark.org.tr/en/user" links to update their incomplete information shown in blue or yellow warnings and update their e-mail addresses and information to the DergiPark system. Otherwise, the e-mails from the journal will not be seen or fall into the SPAM folder. Please fill in all missing part in the relevant field.

Please visit journal's AUTHOR GUIDELINE to see revised policy and submission rules to be held since 2020.